157 related articles for article (PubMed ID: 30587547)
21. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
22. The Correlation Between Histologic, Immunophenotypic, and Molecular Characteristics of Pulmonary Sarcomatoid Carcinoma Reveals That Sarcomatoid Change Is Potentially Derived From Epithelial Carcinoma Cells Undergoing Epithelial-Mesenchymal Transition.
Huang Y; Guo J; Li S; Liu J; Xu J; Ye W; Zhang L; Dong Z; Wu W; Wu C; Hou L
Appl Immunohistochem Mol Morphol; 2023 Jan; 31(1):17-25. PubMed ID: 36165833
[TBL] [Abstract][Full Text] [Related]
23. Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.
Wang L; Yang H; Lei Z; Zhao J; Chen Y; Chen P; Li C; Zeng Y; Liu Z; Liu X; Zhang HT
Oncogene; 2016 Feb; 35(7):867-77. PubMed ID: 25961934
[TBL] [Abstract][Full Text] [Related]
24. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
26. Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition.
Boström AK; Möller C; Nilsson E; Elfving P; Axelson H; Johansson ME
Hum Pathol; 2012 May; 43(5):708-19. PubMed ID: 21992819
[TBL] [Abstract][Full Text] [Related]
27. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
[TBL] [Abstract][Full Text] [Related]
28. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma.
Yang Z; Xu J; Li L; Li R; Wang Y; Tian Y; Guo W; Wang Z; Tan F; Ying J; Jiao Y; Gao S; Wang J; Gao Y; He J
Nat Commun; 2020 Sep; 11(1):4878. PubMed ID: 32985499
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
30. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
Peng S; Sen B; Mazumdar T; Byers LA; Diao L; Wang J; Tong P; Giri U; Heymach JV; Kadara HN; Johnson FM
Oncotarget; 2016 Jan; 7(1):565-79. PubMed ID: 26623721
[TBL] [Abstract][Full Text] [Related]
32. High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.
Rudisch A; Dewhurst MR; Horga LG; Kramer N; Harrer N; Dong M; van der Kuip H; Wernitznig A; Bernthaler A; Dolznig H; Sommergruber W
PLoS One; 2015; 10(4):e0124283. PubMed ID: 25919140
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
34. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
35. EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells.
Liu LC; Tsao TC; Hsu SR; Wang HC; Tsai TC; Kao JY; Way TD
J Agric Food Chem; 2012 Oct; 60(39):9863-73. PubMed ID: 22957988
[TBL] [Abstract][Full Text] [Related]
36. Foxf2 plays a dual role during transforming growth factor beta-induced epithelial to mesenchymal transition by promoting apoptosis yet enabling cell junction dissolution and migration.
Meyer-Schaller N; Heck C; Tiede S; Yilmaz M; Christofori G
Breast Cancer Res; 2018 Oct; 20(1):118. PubMed ID: 30285803
[TBL] [Abstract][Full Text] [Related]
37. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer.
Li C; Wan L; Liu Z; Xu G; Wang S; Su Z; Zhang Y; Zhang C; Liu X; Lei Z; Zhang HT
Cancer Lett; 2018 Apr; 418():185-195. PubMed ID: 29339211
[TBL] [Abstract][Full Text] [Related]
39. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
40. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]